Dr. Savir-Baruch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2160 S 1st Ave
Maywood, IL 60153Phone+1 708-216-8785
Education & Training
Emory University School of MedicineResidency, Nuclear Medicine, 2011 - 2014- Emory University School of MedicineInternship, Surgery, 2010 - 2011
Semmelweis UniversityClass of 2007
Certifications & Licensure
AZ State Medical License 2021 - 2026
IL State Medical License 2014 - 2026
GA State Medical License 2014 - 2025- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment Start of enrollment: 2016 Jun 01
- Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Start of enrollment: 2018 Nov 14
- BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy Start of enrollment: 2018 May 29
Publications & Presentations
PubMed
- 295 citations18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparativ...Jeremie Calais, Francesco Ceci, Matthias Eiber, Thomas A. Hope, Michael S Hofman
The Lancet. Oncology. 2019-09-01 - 49 citationsAnti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.Funmilayo Tade, Michael A. Cohen, Toncred M. Styblo, Oluwaseun Odewole, Anna I. Holbrook
Journal of Nuclear Medicine. 2016-09-01 - 7 citationsProstate Cancer Imaging with 18F-Fluciclovine.Bital Savir-Baruch, David M Schuster
PET Clinics. 2022-10-01
Books/Book Chapters
Press Mentions
Beyond the AJR: PET/MRI Using 68Ga-RM2 Has Superior Performance to MRI Alone in the Localization of Lesions in Patients with Biochemical Failure After Prostate Cancer TreatmentMay 15th, 2024- Independent Clinical Studies Published Regarding Performance of Axumin® (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)July 19th, 2022
- High Rate of Distant Metastases ID’d After PSMA-PET-Guided sRTJune 21st, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
